Aryl and cycloalkyl analogues of AMPA: Synthetic, pharmacological and stereochemical aspects

Bioorganic and Medicinal Chemistry

Volumn 6, Issue 1, 1998, Pages 119-131

  Skjærbæk, Niels ^a   Brehm, Lotte ^a   Johansen, Tommy N ^a   Hansen, Lene M ^a   Nielsen, Birgitte ^a   Ebert, Bjarke ^a   Søby, Karina K ^a   Stensbøl, Tine B ^a   Falch, Erik ^a   Krogsgaard Larsen, Povl ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

AMPA agonist; AMPA antagonist; Conformational analysis; Excitatory amino acid receptor; Functional partial agonism

Indexed keywords

2 AMINO 3 (3 HYDROXY 5 PHENYLISOXAZOL 4 YL)PROPIONIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; EXCITATORY AMINO ACID RECEPTOR; ISOXAZOLE DERIVATIVE; PARTIAL AGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CIRCULAR DICHROISM; CONFORMATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; STEREOCHEMISTRY;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; CEREBRAL CORTEX; CIRCULAR DICHROISM; CORPUS CALLOSUM; DINUCLEOSIDE PHOSPHATES; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID AGONISTS; MOLECULAR CONFORMATION; RADIOLIGAND ASSAY; RATS; RECEPTORS, AMPA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 0031975434     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(97)10017-7     Document Type: Article

References (49)

1. [1] Krogsgaard-Larsen P, Hansen JJ, editors. Excitatory Amino Acid Receptors: Design of Agonists and Antagonists. Chichester: Ellis Horwood, 1992.
2. [2] Collingridge GL, Watkins JC, editors. The NMDA Receptor. Oxford: Oxford University, 1994.
3. [3] Wheal HV, Thomson AM, editors. Excitatory Amino Acids and Synaptic Transmission. London: Academic, 1995.
4. [4] Monaghan DT, Wenthold RJ, editors. The Ionotropic Glutamate Receptors. New Jersey: Humana, 1997.
5. [5] Conn PJ, Patel J, editors. The Metabotropic Glutamate Receptors. New Jersey: Humana, 1994.
6. [6] Danysz W, Parsons CG, Bresink I, Quack G. Drug News Perspect 1995;8:261.
7. [7] Knöpfel T, Kuhn R, Allgeier H. J Med Chem 1995;38: 1417.
8. [8] Deutsch SI, Morihisa JM. Clin Neuropharmacol 1988;11: 18.
9. [9] Greenamyre JT, Young AB. Neurobiol Ag 1989;10:593.
10. [10] Bowen DM. Br J Psychiat 1990;157:327.
11. [11] Madsen U, Ebert B, Krogsgaard-Larsen P. Biomed Pharmacother 1994;48:305.
12. [12] Carlsson M, Carlsson A. Trends Neurosci 1990;13:272.
13. [13] Ulas J, Cotman CW. Schizophrenia Bull 1993;19:105.
14. [14] Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM. Clin Neuropharmacol 1989;12:1.
15. [15] Sams-Dodd F. Behav Pharmacol 1996;7:3.
16. [16] Hansen JJ, Krogsgaard-Larsen P. Med Res Rev 1990; 10:55.
17. [17] Krogsgaard-Larsen P, Ebert B, Lund TM, Bräuner-Osborne H, Sløk FA, Johansen TN, Brehm L, Madsen U. Eur J Med Chem 1996;31:515.
18. [18] Foster AC, Fagg GE. Eur J Pharmacol 1987;133:291.
19. [19] Thomson AM. Prog Neurobiol 1990;35:53.
20. [20] Murphy DE, Schneider J, Boehm C, Lehmann J, Williams K. J Pharmacol Exp Ther 1987;240:778.
21. [21] Ransom RW, Stec NL. J Neurochem 1988;51:830.
22. [22] Braitman DJ, Coyle JT. Neuropharmacology 1987;26: 1247.
23. [23] Honoré T, Nielsen M. Neurosci Lett 1985;54:27.
24. [24] Honoré T, Drejer J, Nielsen EØ, Nielsen M. Biochem Pharmacol 1989;38:3207.
25. [25] Christensen IT, Reinhardt A, Nielsen B, Ebert B, Madsen U, Nielsen EØ, Brehm L, Krogsgaard-Larsen P. Drug Des Del 1989;5:57.
26. [26] Ebert B, Lenz SM, Brehm L, Bregnedal P, Hansen JJ, Frederiksen K, Bøgesø KP, Krogsgaard-Larsen P. J Med Chem 1994;37:878.
27. [27] Ebert B, Madsen U, Lund TM, Lenz SM, Krogsgaard-Larsen P. Neurochem Int 1994;24:507.
28. [28] Ebert B, Madsen U, Søby KK, Krogsgaard-Larsen P. Neurochem Int 1996;29:309.
29. [29] Ebert B, Søby KK, Madsen U, Krogsgaard-Larsen P. In: Fog R, Gerlach J, Hemmingsen R, editors. Schizophrenia - An Integrated View. Copenhagen: Munksgaard, 1995:379-398.
30. [30] Johansen TN, Ebert B, Falch E, Krogsgaard-Larsen P. Chirality 1997;9:274.
31. [31] Tomita K. Ann Sankyo Res Lab 1973;25:1.
32. [32] Frølund B, Kristiansen U, Brehm L, Hansen AB, Krogsgaard-Larsen P, Falch E. J Med Chem 1995;38:3287.
33. [33] Bennouna C, Petrus F, Verducci J. Bull Soc Chim Fr II 1980:478.
34. [34] Begtrup M, Sløk FA. Synthesis 1993:861.
35. [35] Gübitz G, Jellenz W, Santi W. J Liq Chromatogr 1981;4: 701.
36. [36] Gübitz G, Jellenz W, Santi W. J Chromatogr 1981;203: 377.
37. [37] Shinbo T, Yamagushi T, Nishimura K, Sugiura M. J Chromatogr 1987;405:145.
38. [38] Lazareno S, Birdsall NJM. Trends Pharmacol Sci 1993; 14:237.
39. [39] Bang-Andersen B, Lenz SM, Skjærbæk N, Søby KK, Hansen HO, Ebert B, Bøgesø KP, Krogsgaard-Larsen P. J Med Chem 1997;40:2831.
40. [40] Burfield DR, Smithers RH. J Org Chem 1978;43:3966.
41. [41] Still WR, Kahn M, Mitra A. J Org Chem 1978;43:2923.
42. [42] Beck M, Jaunich S, Frahm AW. Arch Pharm 1986;319:29.
43. [43] Quaglia W, Pigini M, Tayebati SK, Piergentili A, Giannella M, Marrucci G, Melchiorre C. J Med Chem 1993; 36:1520.
44. [44] Jacquier R, Petrus C, Petrus F, Verducci J. Bull Soc Chim Fr 1970;5:1978.
45. [45] Jacquier R, Petrus C, Petrus F, Verducci J. Bull Soc Chim Fr 1970;7:2685.
46. [46] Foster AC, Wong EHF. Br J Pharmacol 1987;91:403.
47. [47] Kemp JA, Foster AC, Leeson PD, Priestly T, Tridgett R, Iversen LL, Woodruff GN. Proc Natl Acad Sci USA 1988;85:6547.
48. [48] Harrison NL, Simmonds MA. Br J Pharmacol 1985;84:381.
49. [49] SPARTAN SGI version 4.1.1 GL Wavefunction, Inc., 18401 von Karman Ave., suite no. 370, Irvine, CA 92715.